We overcome the biggest challenge for genetic medicines: Safe and effective delivery. We developed a field-leading proprietary technology for systemic nucleic acid delivery, based on scalable non-immunogenic materials. Our patented data-driven high-throughput screening platform allows us to screen novel nanocarrier formulations at unparalleled scale.
We use our cell-specific nanocarriers to develop mRNA and gene editing therapies for currently incurable diseases. Our pipeline includes immunotherapies, which we strive to advance rapidly into the clinic.
We use our cell-specific nanocarriers to develop mRNA and gene editing therapies for currently incurable diseases. Our pipeline includes immunotherapies, which we strive to advance rapidly into the clinic.
Location: United Kingdom, England, London
Employees: 1-10
Founded date: 2021
Investors 2
| Date | Name | Website |
| - | Y Combinat... | ycombinato... |
| - | Aleka Capi... | alekacapit... |
Mentions in press and media 1
| Date | Title | Description |
| 24.03.2021 | Y Combinator’s biotech startups incubate a new generation of therapies and tools | Medical and biotech had a strong showing at Y Combinator’s latest demo day, with nearly a dozen companies in the space catching my eye. The things a startup can accomplish in this space are astonishing these days, so don’t be surprised if a... |